NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









TheraXyte BioScience

TheraXyte BioScience

Private
BeijingHealthcare & Life Scienceshttp://theraxyte.com/

Last Round

Seed

Jul 11, 2022

Total Funding Raised

$10M

Company Overview

TheraXyte BioScience is a biotechnology company that develops an extracellular vesicle (EV)-mediated drug delivery platform and EV-based novel therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

extracellular vesicle drug deliveryexosome therapeuticsdrug delivery platformexosome CDMOCDMO servicesCRO servicesexosome manufacturingexosome cargo loadingexosome targetingnucleic acid deliverycell line engineeringContract Development and Manufacturing OrganizationContract Research OrganizationGMP manufacturingregenerative medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TheraXyte BioScience Comparables

Compare TheraXyte BioScience with similar companies based on industry and business-model similarity.

TheraXyte BioScience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Evox Therapeutics
81%
ILIAS Biologics Inc.
81%
EXO Biologics
80%

TheraXyte BioScience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJul 11, 2022

Key People

Founding team and executive leadership

TONG ZHAO

Chief Executive Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 5, 2026

    Monthly visitors increased 2249% MoM, from 37 to 869.

  • Jul 11, 2022

    $10M round led by NHH Venture Fund, L.P.

TheraXyte BioScience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TheraXyte BioScience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TheraXyte BioScience's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Employee Range2
Year Founded2019
Last FundingJul 11, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.